ABCA1 and prion disease: Second, treatment with an LXR agonist and overexpression of heterologous ABCA1, treatments that stimulate both cholesterol efflux and ABCA1 abundance, reduce PrPC to PrPSc conversion, thus warranting further consideration as an option for treatment of prion disease.